(IN BRIEF) Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. The trial involved 9,650 … Read the full press release →
Posted in Business, Denmark, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cardiovascular risk, Martin Holst Lange, Novo Nordisk, Oral Semaglutide, Rybelsus®., safety, SOUL Trial Shows, Type 2 Diabetes Patients